<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036946</url>
  </required_header>
  <id_info>
    <org_study_id>REGENERON-VGFT-ST-0103</org_study_id>
    <secondary_id>MSKCC-01131</secondary_id>
    <secondary_id>CDR0000069343</secondary_id>
    <secondary_id>NCI-G02-2065</secondary_id>
    <nct_id>NCT00036946</nct_id>
  </id_info>
  <brief_title>VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>An Open-Label, Sequential Cohort Dose-Escalation Safety, Tolerability And Pharmacokinetic Study Of VEGF Trap In Patients With Incurable, Relapsed Or Refractory Solid Tumors Or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by&#xD;
      stopping blood flow to the cancer.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in patients who have relapsed&#xD;
      or refractory solid tumors or non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of VEGF Trap in patients with incurable relapsed&#xD;
           or refractory solid tumors or non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Evaluate the ability of this drug to bind and inactivate circulating vascular&#xD;
           endothelial growth factor (VEGF) in these patients.&#xD;
&#xD;
        -  Determine the dosing regimen that is optimal for neutralization of circulating VEGF in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine whether antibodies to this drug develop in these patients.&#xD;
&#xD;
        -  Assess, preliminarily, the ability of this drug to alter tumor vascular permeability and&#xD;
           tumor growth in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive VEGF Trap subcutaneously once daily on days 1, 29, 36, 43, 50, 57, and 64 in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of VEGF Trap until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, 5 additional patients&#xD;
      are treated at the MTD.&#xD;
&#xD;
      Patients are followed at 1 and 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <primary_completion_date type="Actual">March 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ziv-aflibercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed incurable primary or metastatic solid tumor or non-Hodgkin's&#xD;
             lymphoma&#xD;
&#xD;
               -  Relapsed after or is refractory (e.g., unresectable) to at least 2 standard&#xD;
                  chemotherapy regimens and rituximab&#xD;
&#xD;
               -  No standard curative surgery, chemotherapy, immunotherapy, other antitumor&#xD;
                  therapy, or radiotherapy options exist&#xD;
&#xD;
          -  No known or suspected squamous cell carcinoma of the lung&#xD;
&#xD;
          -  No prior or concurrent CNS (brain or leptomeningeal) metastases&#xD;
&#xD;
          -  No prior or concurrent primary intracranial tumor by MRI or CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  25 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  No other severe or uncontrolled hematologic condition&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN&#xD;
&#xD;
          -  PT, PTT, and INR normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
          -  No 1+ or greater proteinuria&#xD;
&#xD;
          -  No other severe or uncontrolled renal condition&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Electrocardiogram normal&#xD;
&#xD;
          -  LVEF normal by echocardiogram or MUGA scan within the past 12 months or since&#xD;
             completion of prior anthracycline&#xD;
&#xD;
          -  No severe or uncontrolled cardiovascular condition&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No active coronary artery disease, angina, congestive heart failure, or arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No prior or concurrent peripheral vascular disease, including:&#xD;
&#xD;
               -  Angiographically or ultrasonographically documented arterial or venous occlusive&#xD;
                  event&#xD;
&#xD;
               -  Symptomatic claudication&#xD;
&#xD;
          -  No untreated or uncontrolled hypertension&#xD;
&#xD;
          -  No treated blood pressure more than 160/100 mm Hg on at least 3 repeated&#xD;
             determinations on separate days within the past 6 weeks&#xD;
&#xD;
          -  No symptomatic orthostatic hypotension&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe or uncontrolled pulmonary condition&#xD;
&#xD;
          -  No pulmonary embolism&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior hypersensitivity reactions to any recombinant proteins (e.g., VEGF Trap)&#xD;
&#xD;
          -  No severe or uncontrolled gastrointestinal, immunological, or musculoskeletal&#xD;
             condition&#xD;
&#xD;
          -  No severe or uncontrolled psychiatric or adverse social circumstance that would&#xD;
             preclude study&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-barrier contraception during and for at&#xD;
             least 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent adrenal corticosteroids, except low doses as replacement therapy in&#xD;
             patients who have previously received suppressive doses or for adrenal insufficiency&#xD;
&#xD;
          -  No concurrent systemic hormonal contraceptive agents&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior surgery (except fine needle biopsy/aspiration or&#xD;
             removal/biopsy of a skin lesion)&#xD;
&#xD;
          -  No prior surgical procedure for correction or prophylaxis of peripheral vascular&#xD;
             insufficiency or cerebral ischemic events&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 6 months since prior treatment for acute congestive heart failure&#xD;
&#xD;
          -  At least 30 days since prior investigational drugs&#xD;
&#xD;
          -  No concurrent standard or other investigational anticancer agents&#xD;
&#xD;
          -  No concurrent herbal supplements (&quot;nutraceuticals&quot;)&#xD;
&#xD;
          -  No concurrent anticoagulant or antiplatelet drugs, (e.g., warfarin, heparin, aspirin,&#xD;
             or other non-steroidal anti-inflammatory drugs) except selective cyclo-oxygenase-2&#xD;
             (COX-2) inhibitors for analgesia&#xD;
&#xD;
          -  No concurrent COX-2 inhibitors for tumor treatment or prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob Dupont, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dupont J, Schwartz L, Koutcher J, et al.: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. [Abstract] J Clin Oncol 22 (Suppl 14): A-3009, 197s, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Dupont J, Camastra D, Gordon MS, et al.: Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-776, 2003.</citation>
  </results_reference>
  <results_reference>
    <citation>Tew WP, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, Sabbatini P, Mendelson D, Schwartz L, Gettinger S, Psyrri A, Cedarbaum JM, Spriggs DR. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res. 2010 Jan 1;16(1):358-66. doi: 10.1158/1078-0432.CCR-09-2103. Epub 2009 Dec 22.</citation>
    <PMID>20028764</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

